Each film coated tablet contains: Micronised Flavonoid Extracts Rutaceae 500 mg Eq. to Diosmin 450 mg, Hesperidin 50 mg.
Pharmacology: DIOSMIN + HESPERIDIN (HESPADIN) is a phlebotonic drug and a vascular protecting agent. It reinforces venous tone by prolonging the activity of parietal noradrenaline. Thus Diosmin + Hesperidin (HESPADIN) decreases venous capacitance, venous distensibility, and venous emptying time.
DIOSMIN + HESPERIDIN (HESPADIN) protects the microcirculation by fighting the microcirculation damaging process. It combats venous inflammation by decreasing leukocyte activation, and as a consequence, by inhibiting the release of inflammatory mediators, principally free radicals and prostaglandin. Thus DIOSMIN + HESPERIDIN (HESPADIN) normalizes capillary permeability and strengthens capillary resistance.
DIOSMIN + HESPERIDIN (HESPADIN) acts on the lymphatic system. It improves lymphatic drainage by increasing lymph flow and lymph oncotic pressure.
Pharmacokinetics: Micronization of DIOSMIN + HESPERIDIN (HESPADIN) increases its gastrointestinal absorption compared with nonmicronized Diosmin (urinary excretion 57.9% vs 32.7%). In human studies, the drug is primarily excreted in the faeces after oral administration of the product containing 14C-labelled Diosmin. 14% of the administered dose is excreted via the urine.
The plasma half-life of the drug is 11 hours. The drug undergoes extensive metabolism, as indicated by the presence of various phenol acids in the urine.
Treatment of organic and functional chronic venous insufficiency of the lower limbs with the following symptoms: heavy legs, pain, nocturnal cramps, and edema.
Treatment of hemorrhoids and acute hemorrhoidal disease and attacks.
Route of administration: Oral tablets.
In chronic venous disease: 2 tablets daily.
In hemorrhoidal disease: Acute crisis: 6 tablets daily for 4 days, then 4 tablets daily for 3 days.
Chronic treatment: 2 tablets daily.
No overdose symptoms have been observed. Therefore no special treatment is recommended.
DIOSMIN + HESPERIDIN (HESPADIN) is contra-indicated in patients who have shown hypersensitivity to any of the substances present in the drug.
No special precautions are associated with the use of the product.
Use in Pregnancy: Experimental studies in animal have not demonstrated any teratogenic effects and no harmful effects have been reported in man to date.
Use in Lactation: In the absence of data concerning the diffusion into breast milk, breast-feeding is not recommended during treatment.
Some cases of minor gastrointestinal and autonomic disorders have been reported, but these never required cessation of treatment. Possible side effects to be observed: cutaneous allergies, gastrointestinal disorders, headaches and flushes.
None. No interactions have been reported upon co-administration of DIOSMIN + HESPERIDIN (HESPADIN) with other medicines.
Furthermore, no interaction was observed upon administration of DIOSMIN + HESPERIDIN (HESPADIN) with anticoagulants or warfarin.
Store at temperatures not exceeding 30°C. Protect from light.
C05CA53 - diosmin, combinations ; Belongs to the class of bioflavonoids used as capillary stabilizing agents.